Skip to main content
. Author manuscript; available in PMC: 2015 Aug 8.
Published in final edited form as: Trop Med Int Health. 2015 Jan 6;20(3):380–390. doi: 10.1111/tmi.12442

Figure 3.

Figure 3

T-cell activation among cART-treated suboptimal immune responders before and after use of atorvastatin 80 mg daily vs. placebo. All 30 participants are presented for the 12 weeks on study drug (atorvastatin) vs. placebo. (a) Shows percentages of activated CD4 T cells, (b) shows percentages of activated CD8 T cells, (c) shows percentages of exhausted CD4 T cells and (d) shows percentages of exhausted CD8 T cells. The whiskers represent the interquartile ranges. The non-parametric Mann–Whitney test was used to compare immune activation in the study groups, with statistical significance at P-value ≤ 0.05.